The use of ustekinumab in a patient with severe psoriasis and positive HBV serology

Anais Brasileiros de Dermatologia

Volumn 89, Issue 4, 2014, Pages 652-654

  Steglich, Raquel Bissacotti ^a   Cheinquer, Hugo ^a   Meneghello, Luana Pizarro ^a   Muller, Fernanda Melo ^a   de Carvalho, André Vicente Esteves ^a   Reginatto, Flávia Pereira ^a  

^a Complexo Hospitalar da Santa Casa de Misericordia de Porto Alegre Hospital Sao Jose   (Brazil)

Author keywords

Hepatitis B; Hepatitis B virus; Psoriasis

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 23; ISONIAZID; LAMIVUDINE; USTEKINUMAB; MONOCLONAL ANTIBODY; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CASE REPORT; FOLLOW UP; HEPATITIS B VIRUS; HUMAN; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; SEROLOGY; THORAX RADIOGRAPHY; TUBERCULIN TEST; VIRUS LOAD; DRUG EFFECTS; HEPATITIS B; PHYSIOLOGY; TREATMENT OUTCOME; VIROLOGY; VIRUS ACTIVATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PSORIASIS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84904746515     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/abd1806-4841.20143013     Document Type: Article

References (8)

1. Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management. J Am Acad Dermatol. 2012;67:1349-1361.
2. Arruda LHF, Campbell GAM, Takahashi MDF. Psoriasis. An bras Dermatol, 2001;76:141-167.
3. Uhlenhake EE, Mehregan DA. Ustekinumab: differential use in psoriasis. Clin Cosmet Investig Dermatol. 2011;4:93-99.
4. Fotiadou C, Lazaridou E, Ioannides D. Safety of anti-tumour necrosis factor-a agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature. J Eur Acad Dermatol Venereol. 2011;25:471-474.
5. Koskinas J, Tampaki M, Doumba PP, Rallis E. Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in an HBsAg negative anti-HBs positive patient. Br J Dermatol. 2013;168:679-680.
6. Chiu HY, Chen CH, Wu MS, Cheng YP, Tsai TF. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol. 2013;169:1295-1303.
7. Opel D, Economidi A, Chan D, Wasfi Y, Mistry S, Vergou T, et al. Two cases of Hepatitis B in patients with moderate to severe psoriasis treated with Ustekinumab. J Drugs Dermatol. 2012;11:1498-1501.
8. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis. 2004;63:ii18-ii24.